ALLO Stock Price - Allogene Therapeutics, Inc. logo

ALLO Stock Price

Allogene Therapeutics, Inc.

$0.66
-$0.04(-5.73%)
33
Overall
60
Value
18
Tech
21
Quality
How is this score calculated?
Market Cap
$227.28M
Volume
5.59M
52W Range
$0.82 - $4.46
Target Price
$8.30

ALLO stock price is $0.66 (-5.73% on the day), giving Allogene Therapeutics, Inc. a market cap of $227.28M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.

ALLO Stock Overview

Price
$0.66
Previous close
$0.70
Open
$0.70
Market cap
$227.28M
52-week range
$0.82 - $4.46
1-year price target
$8.30
Sector
Healthcare
Industry
Biotechnology
Exchange
Nasdaq
MarketXLS Rank
33

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 2 clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it provides clinical-stage product, such as LLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors ; Claudin 18.2 for the treatment of gastric and pancreatic cancer; FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

ABCD
1SymbolPriceChangeVol
2ALLO$0.66-5.7%5.59M
3
4
5
6

Get Allogene Therapeutics, Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.